Cargando…

Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease

Animal models have significantly advanced our understanding of Parkinson’s disease (PD). Alpha-synuclein (α-syn) has taken center stage due to its genetic connection to familial PD and localization to Lewy bodies, one pathological hallmark of PD. Animal models developed on the premise of elevated al...

Descripción completa

Detalles Bibliográficos
Autores principales: Duffy, Megan F., Collier, Timothy J., Patterson, Joseph R., Kemp, Christopher J., Fischer, D. Luke, Stoll, Anna C., Sortwell, Caryl E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132025/
https://www.ncbi.nlm.nih.gov/pubmed/30233303
http://dx.doi.org/10.3389/fnins.2018.00621
_version_ 1783354244193058816
author Duffy, Megan F.
Collier, Timothy J.
Patterson, Joseph R.
Kemp, Christopher J.
Fischer, D. Luke
Stoll, Anna C.
Sortwell, Caryl E.
author_facet Duffy, Megan F.
Collier, Timothy J.
Patterson, Joseph R.
Kemp, Christopher J.
Fischer, D. Luke
Stoll, Anna C.
Sortwell, Caryl E.
author_sort Duffy, Megan F.
collection PubMed
description Animal models have significantly advanced our understanding of Parkinson’s disease (PD). Alpha-synuclein (α-syn) has taken center stage due to its genetic connection to familial PD and localization to Lewy bodies, one pathological hallmark of PD. Animal models developed on the premise of elevated alpha-synuclein via germline manipulation or viral vector-mediated overexpression are used to investigate PD pathophysiology and vet novel therapeutics. While these models represented a step forward compared to their neurotoxicant model predecessors, they rely on overexpression of supraphysiological levels of α-syn to trigger toxicity. However, whereas SNCA-linked familial PD is associated with elevated α-syn, elevated α-syn is not associated with idiopathic PD. Therefore, the defining feature of the α-syn overexpression models may fail to appropriately model idiopathic PD. In the last several years a new model has been developed in which α-syn preformed fibrils are injected intrastriatally and trigger normal endogenous levels of α-syn to misfold and accumulate into Lewy body-like inclusions. Following a defined period of inclusion accumulation, distinct phases of neuroinflammation and progressive degeneration can be detected in the nigrostriatal system. In this perspective, we highlight the fact that levels of α-syn achieved in overexpression models generally exceed those observed in idiopathic and even SNCA multiplication-linked PD. This raises the possibility that supraphysiological α-syn expression may drive pathophysiological mechanisms not relevant to idiopathic PD. We argue in this perspective that synucleinopathy triggered to form within the context of normal α-syn expression represents a more faithful animal model of idiopathic PD when examining the role of neuroinflammation or the relationship between a-syn aggregation and toxicity.
format Online
Article
Text
id pubmed-6132025
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61320252018-09-19 Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease Duffy, Megan F. Collier, Timothy J. Patterson, Joseph R. Kemp, Christopher J. Fischer, D. Luke Stoll, Anna C. Sortwell, Caryl E. Front Neurosci Neuroscience Animal models have significantly advanced our understanding of Parkinson’s disease (PD). Alpha-synuclein (α-syn) has taken center stage due to its genetic connection to familial PD and localization to Lewy bodies, one pathological hallmark of PD. Animal models developed on the premise of elevated alpha-synuclein via germline manipulation or viral vector-mediated overexpression are used to investigate PD pathophysiology and vet novel therapeutics. While these models represented a step forward compared to their neurotoxicant model predecessors, they rely on overexpression of supraphysiological levels of α-syn to trigger toxicity. However, whereas SNCA-linked familial PD is associated with elevated α-syn, elevated α-syn is not associated with idiopathic PD. Therefore, the defining feature of the α-syn overexpression models may fail to appropriately model idiopathic PD. In the last several years a new model has been developed in which α-syn preformed fibrils are injected intrastriatally and trigger normal endogenous levels of α-syn to misfold and accumulate into Lewy body-like inclusions. Following a defined period of inclusion accumulation, distinct phases of neuroinflammation and progressive degeneration can be detected in the nigrostriatal system. In this perspective, we highlight the fact that levels of α-syn achieved in overexpression models generally exceed those observed in idiopathic and even SNCA multiplication-linked PD. This raises the possibility that supraphysiological α-syn expression may drive pathophysiological mechanisms not relevant to idiopathic PD. We argue in this perspective that synucleinopathy triggered to form within the context of normal α-syn expression represents a more faithful animal model of idiopathic PD when examining the role of neuroinflammation or the relationship between a-syn aggregation and toxicity. Frontiers Media S.A. 2018-09-04 /pmc/articles/PMC6132025/ /pubmed/30233303 http://dx.doi.org/10.3389/fnins.2018.00621 Text en Copyright © 2018 Duffy, Collier, Patterson, Kemp, Fischer, Stoll and Sortwell. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Duffy, Megan F.
Collier, Timothy J.
Patterson, Joseph R.
Kemp, Christopher J.
Fischer, D. Luke
Stoll, Anna C.
Sortwell, Caryl E.
Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_full Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_fullStr Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_full_unstemmed Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_short Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_sort quality over quantity: advantages of using alpha-synuclein preformed fibril triggered synucleinopathy to model idiopathic parkinson’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132025/
https://www.ncbi.nlm.nih.gov/pubmed/30233303
http://dx.doi.org/10.3389/fnins.2018.00621
work_keys_str_mv AT duffymeganf qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT colliertimothyj qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT pattersonjosephr qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT kempchristopherj qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT fischerdluke qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT stollannac qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT sortwellcaryle qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease